ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1765

Safety of the Recombinant Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with JAKi Drugs
Abstract Number: 1766

COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
Abstract Number: 1767

Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
Abstract Number: 1768

Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
Abstract Number: 1769

Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance Data
Abstract Number: 1770

Prevalence and Incidence of Depression in Patients with Rheumatoid Arthritis: A Systematic Review
Abstract Number: 1771

The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
Abstract Number: 1773

Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US
Abstract Number: 1774

Performance of an Early Triage System for Identification of Patients with Inflammatory Rheumatic Diseases
Abstract Number: 1775

More Than Half of Patients with Osteoarthritis Have Positive Screening for Fibromyalgia And/or Depression, Feasibly Assessed in Routine Care on Indices Within a Single MDHAQ (multidimensional Health Assessment Questionnaire)
Abstract Number: 1776

COVID-19 Cases in Patients Treated with Secukinumab: Analysis from the Global Safety Database
Abstract Number: 1777

A Symptom Checker App Is Better at Classifying Inflammatory Disease Than Physicians Who Are Presented Identical Information
Abstract Number: 1778

More Than Half of RA Patients with a Lifetime History of Mood Disorders or Anxious and Depressed During COVID-19 Pandemic
Abstract Number: 1779

Psychosocial and Health Measures in Systemic Lupus Erythematosus: COVID-19 Pandemic Trends in the Georgians Organized Against Lupus Cohort
Abstract Number: 1780

Improved Overall Survival in Patients with Lung Cancer and Autoimmune Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].